Suzhou Bioreinno Biotechnology Ltd. Co. has identified antibody-drug conjugates comprising antibodies covalently linked to a cytotoxic drug through a linker. They are reported to be useful for diagnosis and treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has disclosed crystalline forms of phosphodiesterase PDE4B2 inhibitors. They are reported to be useful for the treatment of chronic obstructive pulmonary disease, interstitial lung diseases and asthma.
Shandong Xiansheng Maidejin Biological Pharmaceutical Co. Ltd. has prepared and tested cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Chia Tai Qingjiang Pharmaceutical Co. Ltd. has synthesized peptide epoxyketone compounds acting as proteasome inhibitors. They are reported to be useful for the treatment of systemic lupus erythematosus, ulcerative colitis and rheumatoid arthritis.
Shanghai Henlius Biotech Inc. has presented preclinical data on HLX-403, its novel anti-CDH17 antibody-drug conjugate (ADC), highlighting its potential for gastrointestinal cancers. A first-in-human trial is expected to commence in the third quarter of this year.
Researchers from the Sino-American Cancer Foundation and Taipei Medical University have developed a novel nanobody-based CAR T-cell platform directed against C-type lectin-like molecule-1 (CLL-1) for the possible treatment of acute myeloid leukemia (AML).
Exon skipping therapies based on antisense phosphorodiamidate morpholino oligomer (PMO) have great potential to restore dystrophin in the skeletal muscle and treat Duchenne muscular dystrophy (DMD). Entrada Therapeutics Inc. has developed an endosomal escape vehicle conjugated to DMD exon skipping PMOs (exon 51 skipping), ENTR-601-51, for the potential treatment of DMD.
Liminatus Pharma Inc. has announced plans to conduct a phase I trial of IBA-101, a next-generation CD47-blockade antibody designed to work alongside PD-1/PD-L1 checkpoint inhibitors across a range of solid tumors.
Glioblastoma multiforme (GBM) is an aggressive and highly invasive intracranial tumor arising from the malignant transformation of brain and spinal cord cells. To date, surgery followed by adjuvant chemotherapy is the standard therapy for treating GBM, where temozolomide is the only first-line FDA-approved drug for GBM treatment. The aim of this study from Shenzhen University was to test the effect of a novel chloroethyl nitrosourea analog, HJ-03, in the treatment of GBM, which might overcome temozolomide resistance.
RSS
